Agios Pharma (AGIO) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Agios Pharma (AGIO) PT Raised to $80 at Credit Suisse; 'Platform opportunities beyond IDH'
February 15, 2018 8:59 AM ESTCredit Suisse raised its price target on Agios Pharma (NASDAQ: AGIO) to $80.00 (from $66.00) while maintaining a Outperform rating.
... MoreAgios Pharma (AGIO) PT Raised to $90 at Leerink Partners
February 15, 2018 7:33 AM ESTLeerink Partners raised its price target on Agios Pharma (NASDAQ: AGIO) to $90.00 (from $85.00) while maintaining a Outperform rating.
... MoreAgios Pharma (AGIO) PT Raised to $86 at Needham & Company; 'Continued Execution'
February 14, 2018 12:48 PM ESTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $86.00 (from $72.00) while maintaining a Buy rating.
Analyst Chad Messer commented, " Agios made broad progress across its growing pipeline in 2017 and we expect another busy year with their 2nd drug launch and... More
